An anonymous source estimates that $20 billion to $40 billion in capital is waiting to be deployed on Hyperliquid, a decentralized perpetual-futures trading platform. This figure is much higher than the $8.2 billion in deposits recorded on the platform in late October, when its token HYPE was valued near $76. However, this estimate refers to potential future activity rather than confirmed inflows, indicating significant interest and possible growth ahead for Hyperliquid in the digital asset market.
The story about Hyperliquid's potential $20 billion to $40 billion capital deployment comes with Pluang's market snapshot for major cryptocurrencies as of Nov 12, 2026 05:22 WIB: Out of 50 priced assets, 27 rose and 22 fell today. Notable movers include BAL (Balancer) at Rp16,297 with an 11.14% increase and a typical hold time of 85 days, EOS (EOS.IO) at Rp12,649 up 8.13% with 87 days typical hold time, and UNI (Uniswap) at Rp117,501 down 3.70% with a typical hold time of 66 days and Pluang order activity showing 75% sell versus 25% buy.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
